Shimadzu of Kyoto has signed a research and development agreement with Japan's National Cancer Center (NCC) that aims to identify early-stage biomarker candidates and develop them into molecular imaging products capable of providing early diagnosis of cancer.
Shimadzu and NCC plan to pursue technology related to obtaining ultraearly cancer diagnoses through pharmacokinetic analysis in the drug discovery process. Shimadzu's research has been based on the fusion and application of its chromatography, mass spectrometry, and other core analysis and measuring technology with medical imaging.
Shimadzu and NCC have already collaborated on individual projects, such as the development of tomosynthesis technology. Shimadzu sees the new deal as part of an expansion from its core business in the life sciences sector into the implementation of clinically useful medical science and the fusion of imaging diagnostics and molecular imaging.
